Crossing the Chasm: How to Approach Translational Pharmacokinetic–Pharmacodynamic Modeling of Phage Dosing

Documenti analoghi

• Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA‐Based Therapeutics Using a Mechanistic Physiologically‐Based Pharmacokinetic‐Pharmacodynamic Model
  di: Annie Lumen, et al.
  Pubblicazione: (2024)
• First‐in‐Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BMS‐986308: A Renal Outer Medullary Potassium Channel Inhibitor
  di: Sharif I. Soleman, et al.
  Pubblicazione: (2024)
• FDA Experience on CAR T Cell Pharmacokinetics/Pharmacodynamics and Model‐Based Assessments
  di: Million A. Tegenge, et al.
  Pubblicazione: (2025)
• Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease
  di: Pamela Navarro‐Gonzales, et al.
  Pubblicazione: (2024)
• Insights Into Aldosterone Regulation Through Pharmacokinetic–Pharmacodynamic Modeling of an Aldosterone Synthase Inhibitor
  di: Javiera Cortés‐Ríos, et al.
  Pubblicazione: (2025)